Profile data is unavailable for this security.
About the company
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
- Revenue in USD (TTM)62.20m
- Net income in USD-113.67m
- Incorporated2022
- Employees294.00
- LocationZymeworks Inc108 Patriot Drive, Suite AMIDDLETOWN 19709United StatesUSA
- Phone+1 (302) 274-8744
- Fax+1 (302) 655-5049
- Websitehttps://www.zymeworks.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics Inc | 10.01m | -345.20m | 1.04bn | 294.00 | -- | 1.23 | -- | 103.72 | -2.61 | -2.61 | 0.076 | 5.03 | 0.0109 | -- | -- | 30,978.33 | -37.58 | -28.55 | -39.69 | -29.54 | -- | -- | -3,449.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Septerna Inc | 840.00 | -10.27k | 1.09bn | 68.00 | -- | -- | -- | 1,295,586.00 | -0.0003 | -0.0003 | 0.00002 | 0.0037 | -- | -- | -- | 12.35 | -- | -- | -- | -- | -- | -- | -792.86 | -- | -- | -- | 0.00 | -- | -- | -- | 102.06 | -- | -- | -- |
| MiMedx Group Inc | 342.81m | 90.79m | 1.11bn | 895.00 | 15.18 | 6.11 | 11.12 | 3.23 | 0.4961 | 0.4601 | 2.00 | 1.23 | 1.58 | 2.63 | 6.65 | 383,022.30 | 44.93 | -4.14 | 56.00 | -5.90 | 83.37 | 83.61 | 28.37 | -2.70 | 3.53 | 22.35 | 0.0951 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
| 89bio Inc | 0.00 | -288.96m | 1.11bn | 70.00 | -- | 2.93 | -- | -- | -2.91 | -2.91 | 0.00 | 3.56 | 0.00 | -- | -- | 0.00 | -62.93 | -45.50 | -67.67 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0859 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Cogent Biosciences Inc | 0.00 | -227.05m | 1.12bn | 164.00 | -- | 4.31 | -- | -- | -2.48 | -2.48 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -55.22 | -49.53 | -60.02 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Arrivent Biopharma Inc | 0.00 | -74.89m | 1.15bn | 40.00 | -- | 3.86 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Zymeworks Inc | 62.20m | -113.67m | 1.15bn | 294.00 | -- | 3.18 | -- | 18.49 | -1.51 | -1.51 | 0.8306 | 5.23 | 0.1192 | -- | 1.37 | 228,672.80 | -21.79 | -22.58 | -25.64 | -26.90 | -- | -- | -182.75 | -91.17 | -- | -- | 0.00009 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.16bn | 37.00 | -- | 199.26 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Bicara Therapeutics Inc | 0.00 | -64.84m | 1.17bn | 32.00 | -- | -- | -- | -- | -1.25 | -1.25 | 0.00 | 3.72 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| Aurinia Pharmaceuticals Inc | 207.11m | -50.35m | 1.19bn | 300.00 | -- | 3.26 | -- | 5.74 | -0.3508 | -0.3508 | 1.44 | 2.55 | 0.3862 | 0.8006 | 9.20 | 690,350.00 | -9.39 | -25.97 | -10.78 | -28.24 | 86.08 | -- | -24.31 | -137.64 | 4.82 | -- | 0.1778 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.20bn | 267.00 | -- | 7.59 | -- | 4.77 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Pharvaris NV | 0.00 | -122.29m | 1.22bn | 82.00 | -- | 3.42 | -- | -- | -2.56 | -2.56 | 0.00 | 6.60 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 138.71m | -195.54m | 1.27bn | 296.00 | -- | 8.08 | -- | 9.13 | -1.79 | -1.79 | 1.23 | 1.34 | 0.3799 | 1.04 | 3.49 | 468,608.10 | -53.55 | -65.64 | -75.79 | -71.72 | 89.57 | -- | -140.97 | -1,513.03 | 2.38 | -6.19 | 0.5664 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| CareDx Inc | 312.78m | -143.56m | 1.27bn | 635.00 | -- | 4.60 | -- | 4.06 | -2.70 | -2.70 | 5.95 | 5.15 | 0.6395 | 5.75 | 5.29 | 492,559.10 | -29.35 | -17.54 | -34.84 | -20.85 | 65.77 | 65.50 | -45.90 | -27.78 | 3.87 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
Data as of Nov 08 2024. Currency figures normalised to Zymeworks Inc's reporting currency: US Dollar USD
62.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 15 Oct 2024 | 13.44m | 18.91% |
| BVF Partners LPas of 15 Oct 2024 | 5.87m | 8.26% |
| Redmile Group LLCas of 30 Jun 2024 | 5.21m | 7.34% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 4.23m | 5.95% |
| Rubric Capital Management LPas of 30 Jun 2024 | 3.92m | 5.51% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.53m | 4.97% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.63m | 3.71% |
| DWS Investments (UK) Ltd.as of 30 Jun 2024 | 2.27m | 3.19% |
| Credit Suisse Asset Management (Schweiz) AGas of 30 Jun 2024 | 1.83m | 2.57% |
| BNP Paribas Asset Management USA, Inc.as of 30 Sep 2024 | 1.78m | 2.50% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
